TWI873485B - 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 - Google Patents
用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 Download PDFInfo
- Publication number
- TWI873485B TWI873485B TW111146439A TW111146439A TWI873485B TW I873485 B TWI873485 B TW I873485B TW 111146439 A TW111146439 A TW 111146439A TW 111146439 A TW111146439 A TW 111146439A TW I873485 B TWI873485 B TW I873485B
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- bid
- combination
- compound
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285457P | 2021-12-02 | 2021-12-02 | |
| US63/285,457 | 2021-12-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202332431A TW202332431A (zh) | 2023-08-16 |
| TWI873485B true TWI873485B (zh) | 2025-02-21 |
Family
ID=84462534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111146439A TWI873485B (zh) | 2021-12-02 | 2022-12-02 | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| EP4604961A1 (en) * | 2022-10-18 | 2025-08-27 | Pfizer Inc. | Compounds for the treatment of cancer |
| EP4719405A1 (en) * | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| WO2025202871A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202854A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| WO2026133192A1 (en) * | 2024-12-20 | 2026-06-25 | Pfizer Inc. | Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207463A1 (en) * | 2018-04-26 | 2019-10-31 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| WO2020157652A2 (en) * | 2019-01-31 | 2020-08-06 | Pfizer Inc. | Cdk2 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
-
2022
- 2022-12-01 EP EP22821653.7A patent/EP4440575A1/en active Pending
- 2022-12-01 MX MX2024006747A patent/MX2024006747A/es unknown
- 2022-12-01 KR KR1020247021935A patent/KR20240112932A/ko active Pending
- 2022-12-01 IL IL312980A patent/IL312980A/en unknown
- 2022-12-01 US US18/715,085 patent/US20250041277A1/en active Pending
- 2022-12-01 JP JP2024532155A patent/JP2024544625A/ja active Pending
- 2022-12-01 AU AU2022402512A patent/AU2022402512A1/en not_active Abandoned
- 2022-12-01 CA CA3241001A patent/CA3241001A1/en active Pending
- 2022-12-01 WO PCT/IB2022/061652 patent/WO2023100134A1/en not_active Ceased
- 2022-12-01 CN CN202280090883.2A patent/CN118647379A/zh active Pending
- 2022-12-02 TW TW111146439A patent/TWI873485B/zh active
-
2024
- 2024-06-13 ZA ZA2024/04615A patent/ZA202404615B/en unknown
-
2026
- 2026-02-20 AU AU2026201311A patent/AU2026201311A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207463A1 (en) * | 2018-04-26 | 2019-10-31 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| WO2020157652A2 (en) * | 2019-01-31 | 2020-08-06 | Pfizer Inc. | Cdk2 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2026201311A1 (en) | 2026-03-12 |
| IL312980A (en) | 2024-07-01 |
| MX2024006747A (es) | 2024-06-19 |
| US20250041277A1 (en) | 2025-02-06 |
| KR20240112932A (ko) | 2024-07-19 |
| TW202332431A (zh) | 2023-08-16 |
| ZA202404615B (en) | 2025-12-17 |
| WO2023100134A1 (en) | 2023-06-08 |
| CA3241001A1 (en) | 2023-06-08 |
| CN118647379A (zh) | 2024-09-13 |
| EP4440575A1 (en) | 2024-10-09 |
| AU2022402512A1 (en) | 2024-06-20 |
| JP2024544625A (ja) | 2024-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12263141B2 (en) | Methods for treating cancer | |
| TW202332431A (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| JP7445893B2 (ja) | ヒトにおける固形腫瘍の処置のためのC.novyi | |
| CN107864625B (zh) | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 | |
| JP6768682B2 (ja) | メラノーマの処置に使用するためのアピリモド | |
| US20240000783A1 (en) | Combination therapy | |
| JP2019511204A (ja) | コパンリシブバイオマーカー | |
| JP2018512403A (ja) | 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン類の使用 | |
| TW202210076A (zh) | 組合療法 | |
| KR20230113594A (ko) | Pik3ca 돌연변이 암을 치료하기 위한 병용 요법 | |
| TW202329946A (zh) | 用於治療癌症之方法及包含cdk2抑制劑之給藥方案 | |
| RU2849370C1 (ru) | Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака | |
| JP2025512921A (ja) | (19r)-5-クロロ-3-エチル-16-フルオロ-10,19-ジメチル-20-オキサ-3,4,10,11,23-ペンタアザペンタシクロ[19.3.1.02,6.08,12.013,18]ペンタコサ-1(24),2(6),4,8,11,13,15,17,21(25),22-デカエン-22-アミンを使用して固形腫瘍の治療する方法 | |
| US11684672B2 (en) | Combinations of copanlisib with anti-PD-1 antibody | |
| HK40116611A (en) | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer | |
| HK40096012A (en) | Combination therapy | |
| CA2984357C (en) | Methods for treating cancer | |
| TW202535366A (zh) | 達羅他胺(darolutamide)組合braf及mek抑制劑以用於黑色素瘤之治療 | |
| WO2025217597A1 (en) | A cdk9 inhibitor for use in the treatment of cancer in a subject having an asxl1 mutation | |
| EP4719405A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |